- Home
- IONS vs APA Comparison
IONS vs APA Comparison
Compare IONS & APA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- APA
- Stock Information
- Founded
- IONS 1989
- APA 1954
- Country
- IONS United States
- APA United States
- Employees
- IONS N/A
- APA N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- APA Oil & Gas Production
- Sector
- IONS Health Care
- APA Energy
- Exchange
- IONS Nasdaq
- APA Nasdaq
- Market Cap
- IONS 5.9B
- APA 5.6B
- IPO Year
- IONS 1991
- APA N/A
- Fundamental
- Price
- IONS $37.41
- APA $19.86
- Analyst Decision
- IONS Buy
- APA Hold
- Analyst Count
- IONS 18
- APA 17
- Target Price
- IONS $57.59
- APA $23.38
- AVG Volume (30 Days)
- IONS 1.5M
- APA 7.4M
- Earning Date
- IONS 07-31-2025
- APA 07-30-2025
- Dividend Yield
- IONS N/A
- APA 5.03%
- EPS Growth
- IONS N/A
- APA N/A
- EPS
- IONS N/A
- APA 2.76
- Revenue
- IONS $717,253,000.00
- APA $10,148,000,000.00
- Revenue This Year
- IONS $7.98
- APA N/A
- Revenue Next Year
- IONS $16.09
- APA N/A
- P/E Ratio
- IONS N/A
- APA $7.20
- Revenue Growth
- IONS N/A
- APA 24.91
- 52 Week Low
- IONS $23.95
- APA $13.58
- 52 Week High
- IONS $52.34
- APA $33.41
- Technical
- Relative Strength Index (RSI)
- IONS 68.61
- APA 65.58
- Support Level
- IONS $34.78
- APA $20.24
- Resistance Level
- IONS $37.54
- APA $21.34
- Average True Range (ATR)
- IONS 1.06
- APA 0.79
- MACD
- IONS 0.07
- APA 0.20
- Stochastic Oscillator
- IONS 95.44
- APA 78.19
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About APA APA Corporation
APA Corp is an independent exploration and production company. It develops, and produces crude oil, natural gas, and natural gas liquids. The Company's business has oil and gas operations in three geographic areas: the United States (U.S.), Egypt, and offshore the U.K. in the North Sea (North Sea). APA also has active development, exploration, and appraisal operations ongoing in Suriname, as well as exploration interests in Uruguay, Alaska, and other international locations.